FDA 483 - Hubei Gedian Humanwell Pharmaceutical Co., Ltd. - October 17, 2013

An FDA inspection conducted from October 14 to 17, 2013, at Hubei Gedian Humanwell Pharmaceutical Co., Ltd, an Active Pharmaceutical Ingredient (API) manufacturer located in Ezhou, Hubei, China, identified critical deficiencies in the firm's quality management system. The inspection, detailed in an FDA Form 483, highlighted the company's failure to implement adequate controls to safeguard API drug products from adverse effects during their storage period.Specifically, the monitoring system responsible for tracking vital parameters, such as temperature and humidity, within the finished API warehouse (Cool Room) was deemed insufficient. A significant shortcoming was the absence of a backup system or alternative data recording methods, like chart recorders or graphical representations. This deficiency meant there was no reliable way to confirm that deviations from established environmental controls had not occurred, and it impeded thorough investigation into any deviations that did arise during the storage of finished products.These observations underscore the company's obligation to strengthen its quality control processes, especially concerning the environmental monitoring of stored APIs. Hubei Gedian Humanwell Pharmaceutical Co., Ltd is expected to take prompt and effective corrective actions to resolve these issues, ensuring comprehensive oversight of product quality and adherence to pharmaceutical manufacturing standards.